SANTA MONICA, Calif. & REDWOOD CITY, Calif.–(BUSINESS WIRE)– Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe and broadly accessible therapies.
Ayeuna ditalungtik dina percobaan pivotal Fase 2, CART-ddBCMA mangrupikeun terapi T-sél Arcellx ngagunakeun binder sintétik novel perusahaan, D-Domain. Kite sareng Arcellx bakal babarengan maju sareng komersialisasi aset CART-ddBCMA di AS, sareng Kite bakal komersilkeun produk di luar AS.
Terapi T-Cell mobil mangrupikeun salah sahiji pangobatan terobosan pikeun sababaraha jinis kanker getih. Aya leuwih ti 750 lumangsung percobaan klinis in Terapi T-Cell CAR di Cina ayeuna. Pasén anu badé ngadaptar tiasa ngahubungi KankerFax saluran pitulung pasien dina WhatsApp + 91 96 1588 1588 atanapi email ka info@cancerfax.com.
Ngeunaan Arcellx
Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory sababaraha myeloma (r/r MM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.
Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two programs: a Phase 1 study of ACLX-001 for r/r MM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk sindrom myelodysplastic, initiated in the fourth quarter of 2022.
Perkawis Langlayangan
Kite, a Gilead Company, is a global biopharmaceutical company based in Santa Monica, California, focused on cell therapy to treat and potentially cure cancer. As the global cell therapy leader, Kite has treated more patients with CAR T-cell therapy than any other company. Kite has the largest in-house cell therapy manufacturing network in the world, spanning process development, vector manufacturing, clinical trial supply, and commercial product manufacturing.
Ngeunaan Élmu Giléad
Gilead Sciences, Inc. mangrupikeun perusahaan biofarmaseutik anu parantos ngudag sareng ngahontal terobosan dina ubar salami langkung ti tilu dekade, kalayan tujuan nyiptakeun dunya anu langkung séhat pikeun sadaya jalma. Perusahaan komitmen pikeun ngamajukeun obat-obatan inovatif pikeun nyegah sareng ngubaran panyakit anu ngancam kahirupan, kalebet HIV, hépatitis virus sareng kanker. Gilead beroperasi di leuwih ti 35 nagara di sakuliah dunya, jeung kantor pusatna di Foster City, California. Gilead Sciences nampi Kite dina 2017.
